IP Library › Granted Patent US 11,535,899
Granted Patent B2
US 11,535,899 · App. 17/265,060 · Granted Dec 27, 2022

Kit, device and method for detecting prostate cancer

Inventors: Makiko Yoshimoto (Kamakura, JP); Hiroko Sudo (Kamakura, JP); Atsuko Miyano (Kamakura, JP); Satoko Kozono (Kamakura, JP); Takahiro Ochiya (Tokyo, JP); Hiroyuki Fujimoto (Tokyo, JP); Fumihiko Urabe (Tokyo, JP); Juntaro Matsuzaki (Tokyo, JP)
Assignees: TORAY INDUSTRIES, INC.; NATIONAL CANCER CENTER
C12Q1/6886C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,535,899
App. No.
17/265,060
Granted
Dec 27, 2022
Kind
B2
Abstract

This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.

Claims (11)

1. A method for detecting prostate cancer and then treating or performing a diagnostic procedure in a human subject, comprising:

measuring an expression level of has-miR-1185-1-3p in a blood, serum, or plasma sample from the subject;

comparing the measured expression level of hsa-miR-1185-1-3p to a control expression level in a sample from a healthy subject; and

detecting an increased level of hsa-miR-1185-1-3p in the sample from the subject as compared to the control expression level from the sample from the healthy subject,

wherein the increased level of hsa-miR-1185-1-3p indicates that the subject has prostate cancer, and

and further treating the subject for the prostate cancer or performing a diagnostic procedure on the subject with the prostate cancer;

wherein the treating comprises surgery, radiotherapy, chemotherapy or the combination thereof; and

wherein the diagnostic procedure comprises rectal examination, transrectal ultrasonography of the prostate, or imaging of prostate tissue.

2. The method according to claim 1 , wherein the expression level of hsa-miR-1185-1-3p in the sample is measured by using a kit comprising a nucleic acid(s) that specifically binds to hsa-miR-1185-1-3p.

3. The method according to claim 1 , wherein the expression level of hsa-miR-1185-1-3p in the sample is measured by using a device comprising a nucleic acid(s) that specifically binds to hsa-miR-1185-1-3p.

4. The method according to claim 3 , wherein the device further comprises at least one nucleic acid capable of specifically binding to at least one polynucleotide selected from the following other prostate cancer markers: miR-1185-2-3p, miR-197-5p, miR-6076, and/or miR-17-3p, miR-320b, miR-6819-5p, and miR-1228-5p.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2021
From: YOSHIMOTO, MAKIKO; SUDO, HIROKO; MIYANO, ATSUKO; KOZONO, SATOKO; OCHIYA, TAKAHIRO; FUJIMOTO, HIROYUKI; URABE, FUMIHIKO; MATSUZAKI, JUNTARO
To: TORAY INDUSTRIES, INC.; NATIONAL CANCER CENTER
Reel/Frame 055112/0205 →
Priority Claims (1)
JP JP2018-151952 · Aug 10, 2018 · national
Continuity (1)
Related Publication 20210310077A1 · Oct 7, 2021